[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Oh KC, Zang DY: Primary non-Hodgkin's lymphoma of the bladder with bone marrow involvement. Korean J Intern Med; 2003 Mar;18(1):40-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Involvement of the lower urinary tract by advanced non-Hodgkin's lymphoma (NHL) has been reported in up to 13% of cases, but primary NHL of the urinary bladder is very rare.
  • Cystoscopy revealed an edematous broad-based mass on the left lateral wall of the bladder, and transurethral biopsy showed NHL, diffuse large B-cell type.
  • The lesions of the bladder and left urinary tract were nearly completely regressed after two cycles of systemic cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy with simultaneous restoration of urinary function.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Bone Neoplasms / secondary. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lymphoma, Non-Hodgkin / pathology. Prednisone / administration & dosage. Urinary Bladder Neoplasms / pathology. Vincristine / administration & dosage
  • [MeSH-minor] Adult. Biopsy, Needle. Cystoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Urodynamics

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12760267.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Other-IDs] NLM/ PMC4531605
  •  go-up   go-down


2. Kamel EM, Jichlinski P, Prior JO, Meuwly JY, Delaloye JF, Vaucher L, Malterre J, Castaldo S, Leisinger HJ, Delaloye AB: Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies. J Nucl Med; 2006 Nov;47(11):1803-7
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides the presence of known intravesical tumors or undefined renal lesions on the initial PET scan, the inclusion criterion was the appearance of indeterminate or equivocal (18)F-FDG foci that extended along the course of the urinary tract and could not confidently be separated from urinary activity.
  • RESULTS: Forced diuresis coupled with parenteral hydration eliminated any significant (18)F-FDG activity from the lower urinary tract in 31 (97%) of 32 patients after the bladder had been voided 3 successive times.
  • CONCLUSION: Furosemide challenge has the potential to noninvasively resolve the inherent (18)F-FDG contrast handicap in the lower urinary tract.
  • [MeSH-major] Diuresis. Fluorodeoxyglucose F18. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adult. Female. Furosemide / pharmacology. Humans. Male. Middle Aged. Neoplasm Staging / methods. Reproducibility of Results. Tomography, X-Ray Computed / methods. Urinary Bladder Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17079813.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


3. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res; 2002 Jun;8(6):1863-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful.
  • In the present study, we evaluated the significance of the M:E ratio as a predictor for prognosis for patients with TCC in the upper urinary tract (TCC-UUT).
  • EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy.
  • The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD.
  • Moreover, lower expression levels of E-cadherin were associated with fewer recurrences in the urinary bladder.
  • CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / blood supply. Kidney Neoplasms / blood supply. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cadherins / metabolism. Disease Progression. Endothelial Growth Factors / genetics. Endothelial Growth Factors / metabolism. Female. Fibroblast Growth Factor 2 / genetics. Fibroblast Growth Factor 2 / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / metabolism. Kidney Pelvis / metabolism. Lymphokines / genetics. Lymphokines / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Survival Rate. Ureter / metabolism. Urinary Bladder / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060629.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


Advertisement
4. Kwak C, Lee SE, Jeong IG, Ku JH: Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology; 2006 Jul;68(1):53-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract.
  • OBJECTIVES: To evaluate the efficacy of adjuvant systemic chemotherapy in conjunction with surgery in patients with invasive transitional cell carcinoma of the upper urinary tract.
  • Of these 43 patients, 32 were scheduled to receive more than four courses of cisplatin-based chemotherapy.
  • RESULTS: Recurrence was observed in 12 patients (37.5%) who underwent chemotherapy and 7 (63.6%) who did not (P = 0.170).
  • The disease-free survival was lower in the nonchemotherapy group than in the chemotherapy group (P = 0.0439).
  • During the follow-up period, 9 patients (28.1%) in the chemotherapy group died and 9 patients (81.8%) in the nonchemotherapy group died (P = 0.004).
  • Multivariate Cox proportional hazard model analysis revealed that the use of adjuvant chemotherapy (P = 0.006, relative risk = 9.19) and node-positive status (P = 0.008, relative risk = 8.28) were strongly associated with overall survival.
  • In the chemotherapy group, 24 (75%) had side effects due to the treatment; however, fever and gastrointestinal symptoms were the chief adverse effects and were well tolerated.
  • CONCLUSIONS: Our results have indicated that adjuvant systemic chemotherapy may provide therapeutic benefit in patients with invasive transitional cell carcinoma of the upper urinary tract.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy. Ureteral Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16806415.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Radu V, Ion D, Serban MB, Ciurea M: Locally aggressive colonic and rectal cancer--clinical trial. J Med Life; 2010 Jul-Sep;3(3):314-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This clinical trial studies local invasions from primary colonic and rectal cancers (urinary bladder, abdominal wall, small bowls, uterus, vagina, stomach, bile tract, spleen, duodenum, pancreas, ureters, kidneys), with or without undiscovered metastasis.
  • Primary locally aggressive colonic and rectal cancers include tumors that are staged T4N1-2Mx on diagnosis, and are often associated with a lower prognosis than earlier cancers.
  • Radical nuanced surgery is the base of treatment of the locally aggressive colon-rectal cancer.
  • The studies have shown that in certain localizations of the colon-rectal cancer, the locally aggressive forms can be better controlled by using multimodal therapy, including radiotherapy, either external or guided intraoperatory radiotherapy and chemotherapy with much better results.
  • [MeSH-major] Colonic Neoplasms / pathology. Neoplasm Invasiveness / pathology. Rectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Med. 1997;48:191-202 [9046955.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):872-7 [19124803.001]
  • (PMID = 20945823.001).
  • [ISSN] 1844-122X
  • [Journal-full-title] Journal of medicine and life
  • [ISO-abbreviation] J Med Life
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Romania
  • [Other-IDs] NLM/ PMC3019005
  •  go-up   go-down


6. Kanda H, Ishii K, Ogura Y, Imamura T, Kanai M, Arima K, Sugimura Y: Naftopidil, a selective alpha-1 adrenoceptor antagonist, inhibits growth of human prostate cancer cells by G1 cell cycle arrest. Int J Cancer; 2008 Jan 15;122(2):444-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alpha-1 adrenoceptor antagonists are generally prescribed for benign prostate hyperplasia with lower urinary tract symptoms.
  • Here we demonstrate for the first time that naftopidil has growth inhibitory effect in androgen-sensitive and -insensitive human prostate cancer cell lines.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. G1 Phase / drug effects. Naphthalenes / pharmacology. Piperazines / pharmacology. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / metabolism
  • [MeSH-minor] Adrenergic alpha-Antagonists / pharmacology. Animals. Cell Line, Tumor. Cell Proliferation. Cell Separation. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27. Flow Cytometry. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Receptors, Adrenergic, alpha-1 / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17918159.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Intracellular Signaling Peptides and Proteins; 0 / Naphthalenes; 0 / Piperazines; 0 / Receptors, Adrenergic, alpha-1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; R9PHW59SFN / naftopidil
  •  go-up   go-down


7. Ansari MS, Gupta NP: A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int; 2003 Sep;92(4):375-8; discussion 378
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The trial comprised two treatment arms, i.e. patients were randomized to orchidectomy alone or orchidectomy plus lycopene (OL), each of 27 patients.
  • RESULTS: At 6 months there was a significant reduction in PSA level in both treatments, but more marked in the OL group (mean 9.1 and 26.4 ng/mL, P = 0.9).
  • CONCLUSION: Adding lycopene to orchidectomy produced a more reliable and consistent decrease in serum PSA level; it not only shrinks the primary tumour but also diminishes the secondary tumours, providing better relief from bone pain and lower urinary tract symptoms, and improving survival compared with orchidectomy alone.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Carotenoids / therapeutic use. Orchiectomy / methods. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Survival Analysis. Urinary Retention / drug therapy. Urinary Retention / physiopathology. Urinary Retention / surgery. Urination / physiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] BJU Int. 2005 Jan;95(1):192 [15638928.001]
  • [ErratumIn] BJU Int. 2004 Mar;93(4):655
  • (PMID = 12930422.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene
  •  go-up   go-down


8. Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH: Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy? J Urol; 2010 Jan;183(1):56-61
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
  • PURPOSE: We assessed the efficacy of prophylactic intravesical chemotherapy for primary upper urinary tract urothelial cancer after nephroureterectomy during long-term followup.
  • MATERIALS AND METHODS: From January 1985 to June 2007, 196 patients with primary upper urinary tract urothelial cancer were included in this study.
  • We compared the bladder tumor recurrence rate, number of recurrence episodes, time to first bladder tumor recurrence, tumor type, percent of patients with cystectomy and percent who died of urothelial cancer, and the recurrence-free survival rate.
  • There were no significant differences in recurrence type, mean number of bladder tumor recurrences, percent of patients with cystectomy and the cancer specific survival rate.
  • The bladder recurrence rate was lower in group 1 and 2 than in group 3.
  • Mean time to first bladder tumor recurrence was longer in groups 1 and 2.
  • CONCLUSIONS: Intravesical instillation of epirubicin or mitomycin C appears to be well tolerated and effective for preventing bladder recurrence and prolonging time to first bladder recurrence.
  • Patients should receive prophylactic intravesical chemotherapy after nephroureterectomy.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Carcinoma, Transitional Cell / prevention & control. Carcinoma, Transitional Cell / surgery. Epirubicin / administration & dosage. Kidney Neoplasms / prevention & control. Kidney Neoplasms / surgery. Mitomycin / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / prevention & control. Ureteral Neoplasms / surgery
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Care. Retrospective Studies. Time Factors. Young Adult


9. Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M: Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial. J Urol; 2000 Jul;164(1):53-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.
  • PURPOSE: We determined the activity and toxicity of gemcitabine plus cisplatin in patients with inoperable or metastatic transitional cell carcinoma of the urinary tract.
  • Previous adjuvant or neoadjuvant therapy for locally advanced disease was acceptable if it had been completed more than 1 year before study entry.
  • Notably only 7 of the 54 patients (13%) previously received chemotherapy in an adjuvant or neoadjuvant setting.
  • Median time to progression was 23 weeks and median survival was 54 weeks.
  • Treatment was well tolerated.
  • CONCLUSIONS: Combined cisplatin plus gemcitabine is highly active in advanced transitional cell carcinoma of the urinary tract with manageable toxicity.
  • The response rate, time to treatment failure and overall survival appeared to be comparable to those achieved with combined methotrexate, vinblastine, doxorubicin and cisplatin.
  • Conversely toxicity appeared lower.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10840423.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol; 2005 Dec;174(6):2120-3; discussion 2124
Genetic Alliance. consumer health - Transitional cell carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract.
  • PURPOSE: We investigated the prognostic impact of lymphovascular invasion (LVI) and traditional prognostic factors for survival in a large series of patients treated surgically for upper tract transitional cell carcinoma (TCC).
  • We also developed a prognostic factors-based model for risk stratification of upper tract TCC.
  • MATERIALS AND METHODS: We identified a study population of 173 consecutive patients treated surgically for upper tract TCC at our institution between 1980 and 2002.
  • Using this equation the patients were stratified into low risk (grade 1 or 2, LVI negative, stage pT2 or lower), high risk (any tumor grade, LVI positive, stage pT3 or greater) and intermediate risk (all others) groups with significant differences in survival.
  • CONCLUSIONS: In addition to pathological stage and tumor grade, LVI is an independent prognostic factor for disease specific survival in upper tract TCC.
  • Patients in the high and/or intermediate risk groups may benefit from integrated therapies with surgery and postoperative systemic chemotherapy.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Japan / epidemiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280740.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Al-Quran SZ, Olivares A, Lin P, Stephens TW, Medeiros LJ, Abruzzo LV: Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16). Arch Pathol Lab Med; 2006 Jun;130(6):862-6
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma of the urinary bladder and epididymis as a primary manifestation of acute myeloid leukemia with inv(16).
  • Myeloid sarcoma (MS) of the lower urinary tract is rare.
  • The neoplasm was composed predominantly of blasts that expressed CD68, CD117, myeloperoxidase, and lysozyme, with occasional immature eosinophils.
  • Although blood and bone marrow examinations showed no morphologic evidence of leukemia, conventional cytogenetic studies of marrow demonstrated inv(16)(p13q22) in 4 of 20 metaphases; fluorescence in situ hybridization of the bladder neoplasm also showed inv(16).
  • Following chemotherapy, the patient has been in complete remission for 32 months.
  • In our literature review, we identified 7 cases of MS involving bladder, only 3 without evidence of an associated myeloid neoplasm in marrow, none with cytogenetic data.
  • Cytogenetic analysis is useful for both demonstrating minimal marrow disease and classifying MS in paraffin-embedded tissue sections.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 16. Genital Neoplasms, Male / pathology. Sarcoma, Myeloid / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cytarabine / administration & dosage. Cytogenetic Analysis. Disease-Free Survival. Humans. Idarubicin / administration & dosage. In Situ Hybridization. Male. Middle Aged. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740041.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


12. Christie D, Denham J, Steigler A, Lamb D, Turner S, Mameghan H, Joseph D, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, Francis L, Kramar A, D'Este C, Bill D: Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol; 2005 Nov;77(2):117-25
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
  • BACKGROUND AND PURPOSE: To identify contributing factors to delayed rectal and urinary symptoms in a randomised trial comparing different durations of maximal androgen deprivation (MAD), given prior to radiotherapy, for locally advanced prostate cancer.
  • Their delayed normal tissue effects were recorded by their treating doctors using standardised scales and by the patients using a self-assessment questionnaire regularly.
  • Time to occurrence and prevalence data were analysed.
  • RESULTS: Rectal and urinary symptom levels were observed to vary markedly over time in at least 80% of patients, with some indicating lasting resolution of symptoms.
  • Prevalence rates were found to be substantially lower than actuarial probability rates.
  • Obstructive lower urinary tract symptoms were noted to improve during the first 4 years after radiotherapy in approximately 60% of cases in each treatment arm.
  • However, the treatment arm itself was not shown to influence these improvements in other univariate or multivariate analyses.
  • MAD was shown to reduce both time to occurrence and prevalence of delayed proctopathic symptoms, but this effect was confirmed statistically in the 3 month treatment arm only.
  • Multivariate models indicated that higher levels of haemoglobin prior to any treatment may in some way protect against delayed proctopathic symptoms.
  • CONCLUSIONS: Prevalence data provide more clinically meaningful estimates of risk of delayed effects in normal tissues where assessment relies substantially on reported symptom levels.
  • In these tissues consideration of the impact of baseline symptom levels and pathologies, and greatest acute symptom levels in analyses of delayed effects appears mandatory.
  • Obstructive lower urinary symptoms improve over several years in the majority of patients treated for locally advanced prostate cancer by radiotherapy.
  • [MeSH-major] Androgen Antagonists / adverse effects. Fecal Incontinence / etiology. Prostate-Specific Antigen / blood. Prostatic Neoplasms / therapy. Radiotherapy, Conformal / adverse effects. Urinary Incontinence / etiology
  • [MeSH-minor] Age Factors. Aged. Analysis of Variance. Biopsy, Needle. Combined Modality Therapy. Drug Administration Schedule. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Reference Values. Risk Assessment. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16271786.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


13. Caremel R, Pfister C: [Diagnosis and treatment of superficial bladder cancers]. Rev Prat; 2007 Mar 31;57(6):621-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of superficial bladder cancers].
  • [Transliterated title] Diagnostic et traitement des cancers superficiels de la vessie.
  • Gross hematuria is the most common presenting sign of bladder tumour; its finding should always prompt a cystoscopy of the lower urinary tract.
  • The finding of a bladder tumour always requires assessment of the upper urinary tract.
  • Additional treatment with intravesical instillations may be necessary according to the at-risk group defined by the Cancer Committee of the French Urological Association.
  • Intravesical instillations essentially consist of intravesical chemotherapy (mitomycin C) and intravesical immunotherapy (BCG).
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Cystectomy. Diagnostic Techniques, Urological. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593786.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 34
  •  go-up   go-down


14. James ND, Bloomfield D, Luscombe C: The changing pattern of management for hormone-refractory, metastatic prostate cancer. Prostate Cancer Prostatic Dis; 2006;9(3):221-9
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of hormone-refractory prostate cancer is palliative, and surgery and radiotherapy are used for the relief of lower urinary tract symptoms and localized painful bony metastases.
  • Systemic treatments are not widely accepted in this setting, but clinical trials have demonstrated the potential for bone targeting agents such as strontium-89 and the bisphosphonates to palliate painful bone metastases and to delay progression in certain settings.
  • Chemotherapy with mitozantrone in combination with steroids has previously been shown to have palliative benefits and to delay progression.
  • The additional costs incurred by the use of chemotherapy or bone-targeting therapies may be offset by gains in overall care with fewer in-patient admissions compared with steroid monotherapy.
  • Future studies investigating the timing of chemotherapy, combinations with existing treatments or other novel therapies are underway.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Prostatic Neoplasms / therapy
  • [MeSH-minor] Androgen Antagonists / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Clinical Trials as Topic. Combined Modality Therapy / methods. Diphosphonates / therapeutic use. Drug Resistance, Neoplasm. Humans. Male. Mitoxantrone / therapeutic use. Neoplasm Metastasis / therapy. Palliative Care / methods. Prednisolone / therapeutic use. Spinal Cord Compression / drug therapy. Spinal Cord Compression / etiology. Spinal Cord Compression / surgery. Taxoids / therapeutic use. Urologic Diseases / etiology. Urologic Diseases / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801939.001).
  • [ISSN] 1365-7852
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Diphosphonates; 0 / Taxoids; 15H5577CQD / docetaxel; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone
  • [Number-of-references] 64
  •  go-up   go-down


15. Vidal M, Ferrer A, Serrano S, Tobeña M, Pajares I, Lopez D, Millastre E, Ruiz-Echarri M, Lambea J, Tres A: Fever in cancer patients as a cause of attendance in emergency room. J Clin Oncol; 2009 May 20;27(15_suppl):e20706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20706 Background: Normal human body temperature displays a circadian rhythm, ranging from 36.1 C or lower in predawn hours to 37.4 C or higher in the afternoon.
  • Cancer tumor type, 35 had lung cancer (35.7%), 14 had breast cancer (14.3%), 9 had colorectal cancer (9.2%), 9 had urothelial cancer (9.2%), 5 had head neck cancer (5.1%), 5 had pancreatic cancer (5.1%), 3 had esophageal cancer (3%), 2 had prostate cancer (2%), and 14,3% had other neoplasm.
  • 18 patients (18.36%) had been received chemotherapy treatment in a period of 10 days before. they were attended in emergency room.
  • 30 were diagnosed of respiratory tract infection (30,6%), 12 were diagnosed of urinary infection (12.24%).
  • Considering all the patients who presented with fever: 45 patients were sent home with new treatment (45,9%), 6 patients were observed for 24 hours in the emergency room (6.2%) and 47 patients required admission to the hospital (47.9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Volkmer BG, Seidl-Schlick EM, Bach D, Romics I, Kleinschmidt K: Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma. Clin Rheumatol; 2005 Aug;24(4):319-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclophosphamide is a urotoxic agent that increases the incidence of malignant neoplasms of the urinary tract.
  • Whereas there were no recurrences in the upper urinary tract among the patients of group B, 2 of the 22 patients from group A developed cancer of the renal pelvis.
  • In patients with a history of superficial bladder cancer, a single dose of cyclophosphamide poses a significantly increased risk of tumor recurrence in the lower and in the upper urinary tract as well.
  • [MeSH-major] Carcinoma, Transitional Cell / drug therapy. Cyclophosphamide / adverse effects. Neoplasm Recurrence, Local / chemically induced. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cystectomy / methods. Cystoscopy. Female. Humans. Incidence. Infusions, Intravenous. Male. Middle Aged. Mycobacterium bovis. Neoplasm Staging. Probability. Prognosis. Risk Assessment. Survival Analysis. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1984 Nov;11(4):557-66 [6506370.001]
  • [Cites] Br Med J. 1971 Jul 17;3(5767):182 [5109123.001]
  • [Cites] J Rheumatol. 1999 Aug;26(8):1705-14 [10451066.001]
  • [Cites] Urology. 1980 Aug;16(2):145-8 [6250267.001]
  • [Cites] Urol Int. 1993;51(1):49-53 [8333092.001]
  • [Cites] Ann Intern Med. 1996 Mar 1;124(5):477-84 [8602705.001]
  • [Cites] J Urol. 1981 Mar;125(3):424-6 [7206101.001]
  • [Cites] N Engl J Med. 1988 Sep 29;319(13):871 [3412418.001]
  • [Cites] N Engl J Med. 1988 Apr 21;318(16):1028-32 [3352696.001]
  • [Cites] Urologe A. 1986 Jan;25(1):51-4 [3962045.001]
  • [Cites] Arthritis Rheum. 1995 Aug;38(8):1120-7 [7639809.001]
  • [Cites] J Urol. 1988 Nov;140(5):1009-11 [3050150.001]
  • [Cites] Urology. 1978 May;11(5):437-47 [675898.001]
  • [Cites] Arch Pathol Lab Med. 1982 May;106(5):247-9 [6896137.001]
  • [Cites] J Urol. 1983 Jan;129(1):29-32 [6827684.001]
  • [Cites] J Urol. 1996 Dec;156(6):1931-3 [8911359.001]
  • [Cites] Cancer Res. 1977 Aug;37(8 Pt 2):2918-29 [406041.001]
  • (PMID = 16034647.001).
  • [ISSN] 0770-3198
  • [Journal-full-title] Clinical rheumatology
  • [ISO-abbreviation] Clin. Rheumatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


17. Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB: Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol; 2007 Jan-Feb;25(1):38-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of the M.D. Anderson experience in the treatment of bladder sarcoma.
  • OBJECTIVE: To assess the histologic subtypes, clinical presentations, treatment approaches, and treatment-related outcomes of patients with bladder sarcoma.
  • The clinical presentation consisted of gross, painless hematuria in 79% of patients, lower urinary tract symptoms in 16%, and microhematuria in 5%.
  • The primary treatment modalities used were surgery in 16 (84%) patients, chemotherapy in 2 (11%), and palliation in 1 (5%).
  • The rate of local and distal recurrence was 16% and 53%, respectively.
  • [MeSH-major] Sarcoma / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17208137.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


18. Amling CL: Diagnosis and management of superficial bladder cancer. Curr Probl Cancer; 2001 Jul-Aug;25(4):219-78
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial radiologic evaluation usually includes the excretory urography (intravenous pyelography), although further evaluation of the renal parenchyma with ultrasound or computed tomography scanning has been advocated by some.
  • It is important to identify those tumors at risk for recurrence or progression so that adjuvant intravesical therapies can be instituted.
  • Most are given intravesically on a weekly basis, although many studies suggest that a single instillation immediately after transurethral resection may be as good as a longer course of therapy.
  • Although all of these drugs have toxicity, they usually are well tolerated.
  • Intravesical bacille Calmette-Guérin (BCG) is an immunotherapeutic agent that when given intravesically is very effective in the treatment of superficial transitional cell carcinoma.
  • Compared with controls, BCG has a 43% advantage in preventing tumor recurrence, a significantly better rate than the 16% to 21% advantage of intravesical chemotherapy.
  • In addition, BCG is particularly effective in the treatment of carcinoma in situ, eradicating it in more than 80% of cases.
  • In contrast to intravesical chemotherapy, BCG has also been shown to decrease the risk of tumor progression.
  • Unfortunately, adverse effects associated with this prolonged therapy may limit its widespread applicability.
  • In those patients at high risk in whom BCG therapy fails, intravesical interferon-alpha with or without BCG may be beneficial in some.
  • Photodynamic therapy has also been used but is limited by its toxicity.
  • In patients who progress or do not respond to intravesical therapies, cystectomy should be considered.
  • With the development of orthotopic lower urinary tract reconstruction to the native urethra, the quality of life impact of radical cystectomy has been lessened.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / therapy. Immunotherapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] ABO Blood-Group System. Administration, Intravesical. Adult. Aged. Diagnosis, Differential. Female. Hematuria / etiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging / methods. Photochemotherapy. Risk Factors. Surgical Procedures, Operative / methods. Urethra / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11514784.001).
  • [ISSN] 0147-0272
  • [Journal-full-title] Current problems in cancer
  • [ISO-abbreviation] Curr Probl Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 179
  •  go-up   go-down


19. Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Ferrari N, Giacometti M, Bianchi G: Bacille Calmette-Guérin intravesical instillation and erectile function: is there a concern? Andrologia; 2007 Apr;39(2):51-4
MedlinePlus Health Information. consumer health - Erectile Dysfunction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was to evaluate the effect of bacille Calmette-Guérin (BCG) therapy on erectile function in a cohort of male patients affected by non-muscle invasive bladder cancer.
  • Thirty male patients undergoing BCG treatment for non-muscle invasive bladder cancer were enrolled in the study.
  • All subjects underwent a BCG standard schedule therapy (once weekly instillation for 6 weeks).
  • International Index of Erectile Function (IIEF-5) and International Prostate Symptom score (I-PSS) were addressed to the patients during the treatment schedule (at fourth or fifth instillation) and 1 month after the last instillation.
  • The mean IIEF-5 score was 17.6 +/- 6.7 during therapy and 21.7 +/- 2.92 a month after the last instillation (P=0.008).
  • Baseline ED and the association with lower urinary tract symptoms are variables significantly connected with post-treatment results (P=0.016 and 0.00 respectively) whereas the age seems not to be related to ED (P=0.256).
  • It is concluded that BCG treatment is effective for prophylaxis of non-muscle invasive bladder cancer; however, it may induce a high incidence of ED.
  • Although this effect is transient and reversible, erectile failure is another source of psychological distress that adversely affects the quality of life of men undergoing BCG treatment.
  • [MeSH-major] BCG Vaccine / adverse effects. Carcinoma / drug therapy. Erectile Dysfunction / chemically induced. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17430423.001).
  • [ISSN] 0303-4569
  • [Journal-full-title] Andrologia
  • [ISO-abbreviation] Andrologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


20. Takeda T, Kikuchi E, Yuge K, Matsumoto K, Miyajima A, Nakagawa K, Oya M: Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology; 2009 Jun;73(6):1318-22
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discontinuance of bacille Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence.
  • OBJECTIVES: To investigate whether the occurrence of side effects or discontinuance of bacille Calmette-Guérin (BCG) therapy because of side effects is associated with its therapeutic efficacy.
  • METHODS: We analyzed the data from 145 patients who had had nonmuscle-invasive bladder cancer (Stage pTa, pT1, or pTis) and had undergone an initial course of adjuvant BCG therapy after transurethral resection of bladder tumor from 1996 and 2006 at Keio University Hospital.
  • Side effects were classified as minor and major, and the association between the occurrence of side effects or discontinuance of BCG therapy because of side effects and tumor recurrence or progression was analyzed.
  • BCG therapy was discontinued in 19 patients (13.1%) because of severe hematuria in 2, high fever in 8, and severe lower urinary tract symptoms in 9.
  • Multivariate analyses demonstrated that discontinuance of BCG therapy (P = .018) was an independent predictor for tumor recurrence, in addition to multiplicity (P = .043).
  • Multivariate analyses also demonstrated that neither discontinuance of BCG therapy (P = .308) nor the occurrence of side effects (P = .333) was an independent predictor for tumor progression.
  • CONCLUSIONS: Discontinuation of BCG therapy has a significantly deleterious effect on reducing the incidence of tumor recurrence.
  • When major side effects occur, it might be preferable to attempt to mitigate the major side effects to maintain the BCG therapy on schedule.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. BCG Vaccine / administration & dosage. Neoplasm Recurrence, Local / epidemiology. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232694.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / BCG Vaccine
  •  go-up   go-down


21. Lee LS, Thong PS, Olivo M, Chin WW, Ramaswamy B, Kho KW, Lim PL, Lau WK: Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer. Photodiagnosis Photodyn Ther; 2010 Dec;7(4):213-20
Hazardous Substances Data Bank. POLYVINYLPYRROLIDONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.
  • BACKGROUND: Bladder sparing treatment options for high risk non-muscle invasive blader cancer (NMIBC) after intravesical Bacillus Calmette-Guerin (BCG) failure are limited.
  • OBJECTIVE: To evaluate photodynamic therapy (PDT) using chlorin e6-polyvinylpyrrolidone (Ce6-PVP) as a bladder sparing therapy for NMIBC refractory to intravesical BCG therapy.
  • MATERIALS AND METHODS: Between July 2004 and June 2009, patients with recurrent NMIBC after induction intravesical BCG therapy were treated with PDT performed with a 665nm laser and light dosimetry of 10-24J/cm(2).
  • Post treatment lower urinary tract symptoms and bladder capacity were also monitored.
  • RESULTS: Five patients underwent PDT, with a total of seven treatments performed.
  • At a median follow-up of 29 months (mean 25 months, range 6-36 months), two patients were disease free, two patients developed recurrence and one patient progressed to muscle invasive disease.
  • The patient receiving intravenous Ce6-PVP developed an enterovesical fistula 16 months post PDT.
  • CONCLUSIONS: Despite being a small pilot study, intravesical Ce6-PVP mediated PDT is a feasible bladder sparing treatment option for recurrent high risk non-muscle invasive bladder carcinoma in selected individuals.
  • [MeSH-major] Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Photochemotherapy. Povidone / therapeutic use. Protoporphyrins / therapeutic use. Radiation-Sensitizing Agents / therapeutic use. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Aged. Aged, 80 and over. BCG Vaccine / therapeutic use. Feasibility Studies. Female. Humans. Injections, Intravenous. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Treatment Failure

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • [CommentIn] Photodiagnosis Photodyn Ther. 2010 Dec;7(4):221 [21112543.001]
  • (PMID = 21112542.001).
  • [ISSN] 1873-1597
  • [Journal-full-title] Photodiagnosis and photodynamic therapy
  • [ISO-abbreviation] Photodiagnosis Photodyn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / BCG Vaccine; 0 / Photolon; 0 / Protoporphyrins; 0 / Radiation-Sensitizing Agents; 9003-39-8 / Povidone
  •  go-up   go-down


22. Tu WH, Jensen K, Freiha F, Liao JC: A case of prostatic adenocarcinoma recurrence presenting as ductal carcinoma of the prostate. Nat Clin Pract Urol; 2008 Jan;5(1):55-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A 61-year-old man with a history of recurrent prostate cancer presented with obstructive urinary symptoms.
  • He had been diagnosed with locally invasive adenocarcinoma of the prostate 10 years previously and treated with neoadjuvant hormonal and external beam radiation therapies.
  • The patient presented to the urology clinic with worsening lower urinary tract symptoms consisting of nocturia, urgency, and weak stream.
  • Laboratory tests showed no evidence of urinary tract infection, but confirmed a rising PSA level despite low serum testosterone levels.
  • The patient was started on docetaxel-based chemotherapy for hormone refractory recurrence of prostate cancer as ductal carcinoma of the prostate.
  • [MeSH-major] Carcinoma, Ductal / diagnosis. Neoplasm Recurrence, Local. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18185514.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Pan CC, Chiang H, Chang YH, Epstein JI: Tubulocystic clear cell adenocarcinoma arising within the prostate. Am J Surg Pathol; 2000 Oct;24(10):1433-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neoplasms resembling ovarian common epithelial-type tumors, including clear cell adenocarcinomas, rarely occur in the lower urinary tract of men.
  • When they do, they develop in the urethra or urinary bladder.
  • The clinical as well as the pathologic features are consistent with a clear cell adenocarcinoma as seen in the female genital tract rather than a typical prostatic adenocarcinoma.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Fluorouracil / administration & dosage. Humans. Immunohistochemistry. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Proteins / analysis. Testicular Neoplasms / drug therapy. Testicular Neoplasms / secondary. Testicular Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11023108.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


24. Hessissen L, Kanouni L, Kili A, Nachef MN, El Khorassani M, Benjaafar N, Khattab M, El Gueddari Bel K: Pediatric rhabdomyosarcoma in Morocco. Pediatr Blood Cancer; 2010 Jan;54(1):25-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the first two decades of life.
  • The embryonal subtype was the most frequent (73%) and the head and neck was the most common site of disease, followed by the genito-urinary tract and limbs.
  • Chemotherapy was used in all patients; 44% also had a radical surgery and 23% radiation therapy.
  • The event-free survival (EFS) at 10 years was 39% with relapse as the first cause of treatment failure.
  • The rate of treatment abandonment was 37%.
  • However, EFS is lower than that reported elsewhere due to occasional lack of availability of drugs, inadequate local control, and abandonment.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Morocco / epidemiology. Neoplasm Staging. Prognosis. Radiotherapy. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19746454.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Mallén Mateo E, Trívez Boned MA, García García MA, Sancho Serrano C, Allepuz Losa C, Rioja Sanz LA: [Secondary prostatic lymphoma in a kidney transplant patient]. Actas Urol Esp; 2002 Jun;26(6):429-31
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical presentation is similar to that of other lower urinary tract obstructions, in fact prostatic lymphoma must be considered in patients with these symptoms, particularly in patients with prior history of systemic lymphoma.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Humans. Immunosuppressive Agents / adverse effects. Kidney Failure, Chronic / surgery. Male. Neoplasm Recurrence, Local / drug therapy. Nephrostomy, Percutaneous. Remission Induction. Salvage Therapy. Urethral Obstruction / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12189740.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 6
  •  go-up   go-down


26. Klingler HC: New innovative therapies for benign prostatic hyperplasia: any advance? Curr Opin Urol; 2003 Jan;13(1):11-5
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New innovative therapies for benign prostatic hyperplasia: any advance?
  • PURPOSE OF REVIEW: Benign prostatic hyperplasia is the most common human neoplasm and it is the most frequent tumour requiring surgical treatment in men.
  • Not surprisingly, interest centres on either understanding of prostatic growth during ageing or on various medical or interventional treatments.
  • RECENT FINDINGS: Recent publications describe the interaction of various 5alpha-reductase inhibitors on the two 5alpha-reductase isoforms type 1 and 2, giving a potential new insight into the pathogenesis of benign prostatic hyperplasia.
  • Likewise, chronic inflammation increases growth patterns of fibromuscular tissue in benign prostatic hyperplasia similar to wound healing, and a paracrine loop for chronic inflammation with overexpression of interleukin could be identified.
  • Herbal drug treatment for lower urinary tract symptoms seems to be more effective than previously thought.
  • Likewise, alpha-blockers play an important role in treatment of lower urinary tract symptoms with alpha-1 adrenoreceptor antagonists preventing cell proliferation and apoptotic imbalances in prostatic tissue.
  • The effect of alpha-blockers, however, may be limited by severe bladder outlet obstruction with patients at increased risk of treatment failure.
  • Laser prostatectomy and microwave thermotherapy are under consideration as alternative treatments of benign prostatic hyperplasia.
  • Newer alternative treatments like ethanol installation or bipolar plasma kinetic vaporization have been described, but long-term results and larger patients cohort are still lacking.
  • Medical treatment and interventional therapies are evaluated for their safety and efficacy.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Phytotherapy / methods. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Controlled Clinical Trials as Topic. Humans. Hyperthermia, Induced / methods. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Prognosis. Risk Factors. Sensitivity and Specificity. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Benign Prostatic Hyperplasia.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490810.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  • [Number-of-references] 30
  •  go-up   go-down


27. Ahmed K, Hoque R, El-Tawil S, Khan MS, George ML: Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction. World J Surg Oncol; 2008;6:23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adenocarcinoma of the vermiform appendix is a rare neoplasm of the gastrointestinal tract.
  • CASE PRESENTATION: We report a case of appendicular adenocarcinoma found unexpectedly in a 43 year old male who presented with urinary symptoms.
  • The patient was referred for chemotherapy where he received infusional 5 fluorouracil but died 7 months after surgery.
  • CONCLUSION: Patients with atypical manifestations related to right lower abdominal quadrant should be thoroughly investigated with an open mind.
  • Every attempt should be made to make a precise diagnosis through all the available means to direct the treatment along correct lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Arch Surg. 1977 May;112(5):666-7 [856108.001]
  • [Cites] J La State Med Soc. 1991 Nov;143(11):29-31 [1753179.001]
  • [Cites] Tumori. 1993 Dec 31;79(6):447-9 [8171749.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):154-70 [8000994.001]
  • [Cites] Surg Today. 2005;35(2):168-71 [15674503.001]
  • [Cites] Urology. 2004 May;63(5):981-2 [15135001.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):597-605 [12370661.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):695-8 [12370673.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):29-34 [14745249.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(1):113-5 [15053078.001]
  • [Cites] Rozhl Chir. 2005 Jan;84(1):33-6 [15813454.001]
  • (PMID = 18291037.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2277416
  •  go-up   go-down


28. Vogl TJ, Zangos S, Eichler K, Balzer JO, Jacob U, Keilhauer R, Bauer RW: [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases]. Rofo; 2007 Nov;179(11):1174-80
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transarterielle Chemoperfusion des Beckens--Ergebnisse bei symptomatischen Rezidivtumoren und Lymphknotenmetastasen.
  • PURPOSE: To evaluate local transarterial chemoperfusion (TACP) of therapy-resistant, locally recurrent malignant tumors and lymph node metastases in the pelvis with respect to clinical response, tumor response and survival.
  • In the case of clinical and radiological progression, therapy was stopped and the patient was referred to the hospital's tumor board.
  • In the case of radiological response and clinical progression or clinical response and radiological progression, therapy was continued.
  • Therapy could be stopped by the patient at any time.
  • RESULTS: Treatment was tolerated well by all patients.
  • Tumor-related pain, bleeding, restricted mobility of the lower extremities, incontinence, urinary tract obstruction, and constipation were reduced in 9/17, 5/6, 3/3, 1/3, 2/5, and 1/3 of cases (clinical response rate: 54%).
  • CONCLUSION: Since tumor-related complaints were improved in 54% of the cases and control of tumor growth (PR+SD) was achieved in 67% of the cases, TACP for recurrent pelvic malignancies should be considered as a palliative oncological treatment option.
  • [MeSH-major] Lymphatic Metastasis / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arteries. Drug Resistance, Neoplasm. Female. Humans. Injections, Intra-Arterial / adverse effects. Middle Aged. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Perfusion / adverse effects. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805998.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin
  •  go-up   go-down


29. Carver BS, Kattan MW, Scardino PT, Eastham JA: Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int; 2005 Mar;95(4):509-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy.
  • OBJECTIVE: To evaluate men treated with finasteride for lower urinary tract symptoms, who subsequently were diagnosed with prostate cancer and had a radical prostatectomy (RP) at our institution, to determine if finasteride therapy prevented accurate Gleason grade assignment and prediction of biochemical recurrence.
  • Serum prostate-specific antigen (PSA) level, duration of finasteride therapy, biopsy Gleason grade, clinical stage, RP Gleason grade and pathological stage were reviewed.
  • RESULTS The mean duration of finasteride therapy before diagnosis was 23.6 months, the mean serum PSA (doubled to account for finasteride use) 11.02 ng/mL and mean biopsy Gleason score 6.
  • [MeSH-major] Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Prostate / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Neoplasm Staging. Nomograms. Prostate-Specific Antigen / blood. Urination Disorders / drug therapy. Urination Disorders / etiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1499-507 [10334537.001]
  • [Cites] Urol Clin North Am. 1999 Aug;26(3):465-79 [10494285.001]
  • [Cites] JAMA. 1997 May 14;277(18):1445-51 [9145716.001]
  • [Cites] J Natl Cancer Inst. 1998 May 20;90(10):766-71 [9605647.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):215-24 [12824459.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):111-20 [1989458.001]
  • [Cites] Prostate. 1991;18(3):215-27 [1850515.001]
  • [Cites] Eur Urol. 1993;24(4):461-5 [8287886.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):86-93 [8540613.001]
  • [Cites] Urology. 1999 Apr;53(4):696-700 [10197843.001]
  • [Cites] Urology. 1997 Mar;49(3A Suppl):16-22 [9123731.001]
  • (PMID = 15705069.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092629
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS16077; NLM/ PMC1939940
  •  go-up   go-down






Advertisement